Physician profile
Russell Silverman
NPI 1700808250
$2,436.24
in general payments reported to CMS, 2019-2025
28 companies · $248 in 2025
The $248 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $498 · 2020: $244 · 2021: $130 · 2022: $635 · 2023: $393 · 2024: $289 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $908 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.14 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $361.95 | 2019-2022 | |
| Amgen INC. | $236.07 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $205.92 | 2021-2023 | Assurity |
| Merck Sharp & Dohme LLC | $150.94 | 2022-2025 | Verquvo |
| Bayer Healthcare Pharmaceuticals INC. | $139.27 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $132.29 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $106.55 | 2019-2023 | Farxiga |
| Sanofi-Aventis U.S. LLC | $105.44 | 2019-2024 | |
| Pfizer INC. | $100.98 | 2019-2025 | |
| Scpharmaceuticals INC. | $100.35 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $93.10 | 2019-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $76.57 | 2019-2025 | Lifevest |
| Medtronic Vascular, INC. | $74.34 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $67.68 | 2019-2024 | Evkeeza |
| Impulse Dynamics (USA) INC. | $60.71 | 2023-2025 | Optimizer, Optimizer |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $54.78 | 2019 | |
| Edwards Lifesciences Corporation | $53.64 | 2019-2020 | |
| Abiomed | $45.21 | 2019-2025 | |
| Medtronic, INC. | $41.36 | 2021-2024 | Aurora Ev-Icd Mri Surescan |
| Astellas Pharma US INC | $36.72 | 2019 | |
| Gilead Sciences, INC. | $34.02 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.74 | 2019-2020 | |
| Akcea Therapeutics, INC. | $31.32 | 2020 | |
| Kestra Medical Technology Services, INC. | $25.92 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $21.96 | 2022 | |
| Vifor Pharma, INC. | $18.97 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $14.25 | 2024 | |
| Celonova Biosciences, INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Russell Silverman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.